Dinutuximab beta
As of the edition of 20 October 2026, Dinutuximab beta is an antibody: marketed, first approved in 2017 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Antibody
- Brand name
- Qarziba
- First approved
- 8 May 2017 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Recordati
- Registered trials
- 13, 0 stopped early
- Disease areas
- Cancer; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 3 | 0 |
| Phase 2 | 7 | 2 | 3 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Recordati | Applicant | 2017 to now |